Categories: HealthTechInvestmentMedtechProductVitamin
Alkeus Pharmaceuticals is a late-stage company developing treatments for serious causes of blindness. Alkeus' Lead Product, ALK-001, is a chemically-modified vitamin A that slows formation of toxic vitamin A dimers.
Location: United States, Massachusetts, Cambridge
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.06.2023 | Series B | $150M | - |
Mentions in press and media 11
| Date | Title | Description |
| 10.09.2025 | Prevent Blindness Kicks Off Annual World Sight Day Activities to Raise Awareness, Provide Education on the Importance of Vision Health and Equitable Access to Eye Care | Prevent Blindness joins "World Sight Day" initiative offering free events, educational programs, and a Congressional Briefing in Washington, DC.
Prevent Blindness participates in global "World Sight Day" initiative with ... |
| 07.05.2024 | Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C. | Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024.
Three-day event brings together patients, care partners, and public health champions to ad... |
| 24.04.2024 | Prevent Blindness Declares May as First-ever Inherited Retinal Disease (IRD) Genetic Testing Awareness Month | Prevent Blindness declares the month of May as "Inherited Retinal Disease Genetic Testing Awareness Month."
Prevent Blindness expands IRD and genetic testing awareness initiative to educate patients on various forms of IRDs, and t... |
| 10.01.2024 | Alkeus Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression | - |
| 03.11.2023 | Alkeus Presents Positive Gildeuretinol Trial Results Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease | - |
| 07.06.2023 | Alkeus Pharmaceuticals Raises $150M in Series B Financing | Alkeus Pharmaceuticals, a Cambridge, MA-based biopharmaceutical company that specializes in eye diseases, has raised $150 million in Series B funding.
The round was led by Bain Capital Life Sciences, with additional participation by TCGX, W... |
| 05.06.2023 | Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease | - |
| 05.06.2023 | Alkeus Announces $150 Million Series B Financing | - |
| 05.06.2023 | Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease | - |
| 01.02.2016 | Start-ups selected for MassChallenge Startup Summit in Geneva | |
| - | Alkeus Pharmaceuticals | “Alkeus Pharmaceuticals Inc | Transformation in Sight” |
Show more
Reviews 0
